Savara (NASDAQ: SVRA) reported Q4 EPS of ($0.72), $0.31 worse than the analyst estimate of ($0.41).

“Results from the open-label period of IMPALA reaffirm our strong belief that Molgradex could improve outcomes for patients with aPAP, a rare and debilitating lung disease,” said Rob Neville, Chief Executive Officer, Savara. “We continue our conversations with the FDA, as our highest priority is to get clarity from the agency regarding the design and endpoints of a second Phase 3 study in aPAP.”

For earnings history and earnings-related data on Savara (SVRA) click here.